Get the Stockscreener App
1.65
2.37%
-0.04
After Hours:
1.66
0.01
+0.61%
Immuneering Corp Stock (IMRX) Latest News
Alkermes (NASDAQ:ALKS) & Immuneering (NASDAQ:IMRX) Head to Head Contrast - Armenian Reporter
Needham & Company LLC Reaffirms "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immuneering and Regeneron partner on lung cancer trial - MSN
Immuneering and Regeneron partner on lung cancer trial By Investing.com - Investing.com UK
Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan
Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World
Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat
Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL
Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat
Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Immuneering reports progress in pancreatic cancer trial - Investing.com
Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider
Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80 - Defense World
Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital - Defense World
Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital - MarketBeat
Immuneering reports promising mid-stage readout for pancreatic cancer therapy - FirstWord Pharma
Wall Street-Heavily Traded - WDRB
Immuneering announce data update from Phase 2a trial of IMM-1-104 - TipRanks
Immuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Why Is Immuneering Stock Trading Higher On Tuesday? - AOL
Immuneering touts positive pancreatic cancer data for MEK inhibitor - Endpoints News
Exciting Cancer Therapy Breakthrough! Immuneering’s New Trial Results Amaze - elblog.pl
Immuneering Corp reports promising clinical trial data - Investing.com India
Immuneering Surges Amid Promising Trial Data! What’s Driving the Surge? - Reporteros del Sur -
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - Markets Insider
Pre-Market Boost For Immuneering (IMRX) As Trial Data Impresses Investors - Stocks Telegraph
Immuneering stock jumps on lead asset data (IMRX:NASDAQ) - Seeking Alpha
Immuneering stock soars on promising pancreatic cancer trial results By Investing.com - Investing.com South Africa
Immuneering stock soars on promising pancreatic cancer trial results - Investing.com India
Immuneering (IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - StreetInsider.com
Immuneering Announces Positive Data Update from Three - GlobeNewswire
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):